NeoRecormon & Epogin Sales Down
Posted on July 21, 2008
Filed Under Biopharmaceuticals, Erythropoietin Stimulating Agents
Roche NeoRecormon and Chugai Epogin sales have been affected by pricing pressure in a highly competitive market. In Europe sales of NeoRecormon, Roche’s anemia medicine, declined by 10% due to a general downward pricing pressure on erythropoietin-stimulating agents following the entry of several new biosimilar versions of epoetin alfa. In Japan sales of Epogin declined by 23% due to competitive pressure and the latest government-mandated price cuts, which came into force in April.
Comments
Leave a Reply
You must be logged in to post a comment.